Wellmer S, Wellmer J, Bauer J
Klinik für Epileptologie, Universitätsklinikum Bonn, Sigmund-Freud-Strasse 25, 53105, Bonn.
Nervenarzt. 2008 Dec;79(12):1416, 1418-23. doi: 10.1007/s00115-008-2514-2.
Evaluation of efficacy and tolerability of zonisamide (ZNS) used as an add-on treatment in patients with chronic focal epilepsies.
Retrospective data analysis in 74 patients (38 men, 36 women), age 17-61 years (mean 35 years). Duration of epilepsy was 2-50 years (mean 23.3 years). Additional antiepileptic drugs 2-5 (mean 2.7).
The ZNS daily dosage varied between 100 mg and 500 mg (mean 368 mg). Seizure frequency could be estimated in 50 patients; it decreased by at least 50% in 11 patients (22%), remained unchanged in 28 patients (56%), and increased by at least 50% in 11 patients (22%). None of the patients achieved complete seizure control. Side effects were seen in 45/74 patients (60.8%). Adverse events resulting in discontinuation of treatment with ZNS were documented in 24 patients (32.4%). Out of 70 patients, 34 (48.5%) remained on ZNS 12 months after the onset of therapy.
In this study, ZNS proved to be an antiepileptic drug with a comparatively low anticonvulsant efficacy as an add-on treatment in patients with chronic focal epilepsies.
评估唑尼沙胺（ZNS）作为慢性局灶性癫痫患者附加治疗药物的疗效和耐受性。
对74例患者（38例男性，36例女性）进行回顾性数据分析，年龄17 - 61岁（平均35岁）。癫痫病程为2 - 50年（平均23.3年）。联合使用的抗癫痫药物为2 - 5种（平均2.7种）。
ZNS的日剂量在100毫克至500毫克之间（平均368毫克）。50例患者的癫痫发作频率可评估；11例患者（22%）发作频率至少降低50%，28例患者（56%）保持不变，11例患者（22%）发作频率至少增加50%。无一例患者实现癫痫发作完全控制。45/74例患者（60.8%）出现副作用。24例患者（32.4%）记录有导致停用ZNS治疗的不良事件。70例患者中，34例（48.5%）在治疗开始12个月后仍继续使用ZNS。
在本研究中，唑尼沙胺作为慢性局灶性癫痫患者的附加治疗药物，其抗惊厥疗效相对较低。
